Workflow
UnitedHealth(UNH) - 2024 Q4 - Annual Report

Membership and Service Coverage - UnitedHealthcare Employer & Individual provides access to medical services for 29.7 million people as of December 31, 2024[33]. - UnitedHealthcare Medicare & Retirement served 7.8 million people through its Medicare Advantage products as of December 31, 2024[40]. - UnitedHealthcare enrolled 10.1 million people in the Medicare Part D programs as of December 31, 2024[42]. - UnitedHealthcare Medicare & Retirement served 4.3 million seniors through various Medicare Supplement products as of December 31, 2024[43]. - UnitedHealthcare Community & State served more than 7.4 million people as of December 31, 2024[45]. - UnitedHealthcare Community & State participated in programs in 33 states and the District of Columbia as of December 31, 2024[45]. - UnitedHealthcare Community & State served 1.2 million people through Medicaid expansion programs in 20 states under the ACA as of December 31, 2024[45]. - Through the HouseCalls program, nurse practitioners performed 2.9 million clinical preventive home care visits in 2024[41]. Financial Performance - Total revenues for the year ended December 31, 2024, were 400.3billion,anincreaseof7.7400.3 billion, an increase of 7.7% from 371.6 billion in 2023[250]. - Net earnings attributable to UnitedHealth Group common shareholders for 2024 were 14.4billion,adecreaseof35.514.4 billion, a decrease of 35.5% from 22.4 billion in 2023[250]. - The company's medical costs payable increased to 34.2billionin2024from34.2 billion in 2024 from 32.4 billion in 2023, reflecting a growth of 5.7%[248]. - Basic earnings per share attributable to UnitedHealth Group common shareholders decreased to 15.64in2024from15.64 in 2024 from 24.12 in 2023, a decline of 35.5%[250]. - Net earnings for 2024 were 15,242million,adecreaseof34.215,242 million, a decrease of 34.2% compared to 23,144 million in 2023[252]. - Comprehensive income attributable to UnitedHealth Group common shareholders was 18,045millionin2024,downfrom18,045 million in 2024, down from 23,747 million in 2023, reflecting a decline of 24.0%[252]. - Total comprehensive income for 2024 was 18,882million,downfrom18,882 million, down from 24,510 million in 2023, representing a decrease of 23.1%[252]. - Cash flows from operating activities for 2024 were 24,204million,downfrom24,204 million, down from 29,068 million in 2023, a decrease of about 17%[256]. Investment and Financial Assets - As of December 31, 2024, the company's goodwill and other intangible assets had a carrying value of 130billion,representing44130 billion, representing 44% of total consolidated assets[121]. - The company had 33 billion in financial assets with interest rates varying with market rates, impacting investment income[230]. - The company has 27billioninfinancialliabilitiesatinterestratesthatalsovarywithmarketrates,whichcouldaffectcashflows[230].Thefairvalueofthecompanysfixedrateinvestmentsanddebtissensitivetomarketinterestratechanges,with27 billion in financial liabilities at interest rates that also vary with market rates, which could affect cash flows[230]. - The fair value of the company's fixed-rate investments and debt is sensitive to market interest rate changes, with 46 billion in fixed-rate debt securities and 49billioninnonswappedfixedratetermdebt[231].Thecompanyreportedtotalunrealizedgains(losses),netoftax,of49 billion in non-swapped fixed-rate term debt[231]. - The company reported total unrealized gains (losses), net of tax, of 22 million in 2024, a significant decrease from 876millionin2023[252].Thecompanyincurredcashflowsusedforinvestingactivitiesof876 million in 2023[252]. - The company incurred cash flows used for investing activities of 20,527 million in 2024, compared to 15,574millionin2023,anincreaseofabout31.915,574 million in 2023, an increase of about 31.9%[256]. - As of December 31, 2024, total pharmaceutical manufacturer rebates receivable amounted to 12.5 billion, up from 11.0billionin2023,representinga13.611.0 billion in 2023, representing a 13.6% increase[285]. - The Company reported prepaid expenses and other current assets, including pharmaceutical drug and supplies inventory, of 3.8 billion as of December 31, 2024, compared to $2.8 billion in 2023, indicating a 35.7% increase[286]. Regulatory and Compliance Risks - The company is subject to various federal and state regulations that may impact its ability to manage pharmacy provider networks and drug costs[62]. - The company is subject to uncertain and rapidly evolving laws and regulations related to health data and health information technologies, which could materially affect its competitive landscape and compliance requirements[92]. - The company faces regulatory risks in its pharmacy care services, which could affect operational performance and financial results[140]. - Changes in Medicaid eligibility and reimbursement rates could materially affect the company's revenues and member enrollments[134]. - The company must maintain quality star ratings to qualify for bonus payments under Medicare Advantage, impacting revenue potential[136]. Competition and Market Position - The company operates in a highly competitive market, facing competition from both startups and established Fortune 50 enterprises[68]. - The company faces significant competition in all markets, and its competitive position may be adversely affected by significant merger and acquisition activity among competitors[103]. - The company’s success depends on its ability to develop and deliver innovative products and services to meet evolving market demands, particularly in value-based care models[104]. Operational and Strategic Risks - The company employs extensive judgment in estimating benefit expense payments, which are subject to considerable variability[85]. - The integrity and availability of data are critical for the company's operations, and failures could lead to significant adverse consequences[88]. - The company relies on third-party vendors to process, store, and transmit large amounts of data, which exposes it to risks outside its direct oversight and control[95]. - The company faces risks in managing strategic alliances and acquisitions, which could adversely affect its operations and financial position[111]. - Successful acquisitions require effective integration into existing operations, and failure to do so may lead to increased costs and operational risks[112]. - Public health crises and natural disasters could materially impact the company's business operations and financial performance[113]. - Unfavorable economic conditions may lead to reduced demand for the company's products and services, affecting premium and fee revenues[115]. - A prolonged unfavorable economic environment could constrain government budgets, resulting in reduced reimbursements for health care coverage programs[116]. Employee and Workforce Management - The company has a workforce of nearly 400,000 employees, including over 140,000 clinical professionals, focused on improving health outcomes[71]. - The company prioritizes pay equity and regularly evaluates compensation practices based on performance, age, experience, gender, ethnicity, and race[73]. - The company is committed to developing an inclusive environment and maintaining a diverse talent pipeline through various programs[72]. Cybersecurity and Data Protection - The company has previously reported a cyberattack in 2024 involving its Change Healthcare business, which compromised protected health information[93]. - The company relies on legal protections for its proprietary rights, and any failure to protect these rights could adversely affect its market position[122].